Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment

NCT03446001 is registered in ClinicalTrials.gov with TauRx Therapeutics Ltd as lead sponsor.

NCT NCT03446001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03446001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment
Lead sponsor
TauRx Therapeutics Ltd
Phase
Phase 3
Overall status
Completed
Start date
December 1, 2017
Completion date
April 4, 2023
Enrollment
598 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease